Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Nov
15
Today In Oncology
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In Case You Missed It: Roundup From ESMO Congress 2024
Exploring Issues in Oncofertility
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo